Welcome to our dedicated page for ARGAN SEC filings (Ticker: AGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Argan, Inc. SEC filings document the company’s operating results, material events and governance as a NYSE-listed construction services issuer. Recent 8-K filings report quarterly and fiscal financial results, cash dividends, share repurchase program actions, and engineering, procurement and construction contract developments involving Gemma Power Systems and power-generation projects.
Proxy materials cover board elections, executive compensation, equity awards, shareholder voting matters and related governance disclosures. The filings also identify Argan’s common stock registration and formal event reporting for capital allocation and project-backlog developments.
Argan, Inc. is a Delaware holding company whose main business is large engineering and construction projects across three segments: Power, Industrial and Teledata. The Power segment dominates results, generating $756.5 million of revenue in Fiscal 2026, or 80.1% of consolidated revenue, with a project backlog of over $2.7 billion as of January 31, 2026, up from approximately $1.3 billion a year earlier.
The Industrial segment produced $167.6 million of revenue, and the Teledata segment $20.6 million. Argan maintains a $35.0 million revolving credit facility with an accordion feature of $30.0 million and a separate $25.0 million letter-of-credit facility, with no borrowings outstanding and a $0.3 million letter of credit issued as of January 31, 2026.
The company paid increasing quarterly cash dividends, raising the regular dividend to $0.50 per share for the quarter ended October 31, 2025, and continued share repurchases under a program authorized up to $150 million. Key risks highlighted include heavy reliance on large EPC power projects, fixed-price contract exposure, labor and supply chain pressures, natural gas and power market dynamics, evolving regulation, cybersecurity (including a previously disclosed $2.7 million fraud loss), and ongoing contract litigation at a U.K. subsidiary involving a $10.0 million on-demand bond draw now recorded as accounts receivable.
Argan, Inc. reported strong fourth quarter and full-year results for the period ended January 31, 2026. Q4 revenues were $262.1 million with net income of $49.2 million, or $3.47 per diluted share, and gross margin improved to 25.0%.
For fiscal 2026, revenues reached $944.6 million and net income was $137.8 million, or $9.74 per diluted share, with gross margin rising to 20.5%. Year-end cash, cash equivalents and investments totaled $894.98 million and net liquidity was $421.0 million, with no debt.
Project backlog grew sharply to approximately $2.9 billion as of January 31, 2026, supported by $2.5 billion in new contract value added during the year. The company also increased cash dividends per share to $1.75 for fiscal 2026.
Argan Inc ownership disclosure: The Vanguard Group filed an Amendment No. 5 to Schedule 13G/A reporting 0 shares beneficially owned, representing 0% of Argan Inc common stock as disclosed in the amendment. The filing explains an internal realignment effective 01/12/2026 under SEC Release No. 34-39538 that led certain Vanguard subsidiaries and business divisions to report holdings separately.
Argan, Inc. director John R. Jeffrey Jr. reported an open-market sale of common stock. On January 27, 2026, he sold 5,000 shares of Argan common stock at an average price of $360.78 per share. After this transaction, he held 8,192 shares directly and 8,000 shares indirectly through a John R. Jeffrey IRA.
Argan, Inc. insider John R. Jeffrey, Jr. has filed a notice of proposed sale of 5,000 shares of common stock through Charles Schwab on or about 01/27/2026, to be sold on the NYSE. The filing lists an aggregate market value for these planned sales of $1,795,400 and notes that 13,873,410 shares of common stock were outstanding.
The shares to be sold are tied to an equity grant of 8,636 common shares acquired on 01/16/2026 via option exercise. The notice also reports that during the prior three months, Jeffrey sold 2,700 shares of common stock on 01/20/2026 for gross proceeds of $1,027,620. By signing, the seller represents that he is not aware of undisclosed material adverse information about Argan’s current or prospective operations.
Argan Inc. director Cynthia A. Flanders reported an open-market sale of company stock. On January 21, 2026, she sold 19,000 shares of Argan common stock at an average price of $386.70 per share. After this transaction, she directly owned 26,207 shares of Argan common stock. The filing classifies her as a director and shows that the transaction involved non-derivative securities only, with no associated options or other derivative instruments.
Argan Inc. director John R. Jeffrey Jr. reported option exercises and a share sale. On January 16, 2026, he exercised an option to purchase 10,000 shares of Argan common stock at $45.75 per share using a net settle method, resulting in 8,636 shares of common stock being acquired. On January 20, 2026, he sold 2,700 shares of Argan common stock on the open market at an average price of $380.60 per share. After these transactions, he directly owned 13,192 shares of common stock and indirectly owned 8,000 shares through a John R. Jeffrey IRA, and held 11,500 stock options following the option exercise.
Argan Inc. director William F. Leimkuhler reported a sale of company stock. On January 16, 2026, he sold 11,044 shares of Argan Inc. common stock at an average price of $379.15 per share, as shown in the Form 4 filing.
After this transaction, he beneficially owned 49,939 shares of Argan Inc. common stock in direct ownership. This filing reflects a routine insider transaction and does not by itself describe any change in the company’s operations or financial performance.
An insider of the issuer of AGX filed a Form 144 notice to sell 2,700 shares of common stock. The planned sale has an aggregate market value of 1,002,726 and is expected to be executed around 01/20/2026 through Charles Schwab & Co. Inc. on the NYSE.
The 2,700 shares were acquired on 12/16/2025 via a time-based restricted stock issuance from the issuer, with the full amount received on that date. The filing also notes that 13,873,410 shares of the issuer’s common stock were outstanding, providing context for the size of the planned sale.
A shareholder of AGX has filed a notice of proposed sale under Rule 144 for up to 19,000 shares of common stock. The shares are to be sold through Merrill Lynch, with an aggregate market value of $5,880,500, and the sale is targeted to occur around January 20, 2026 on the NYSE.
The notice also shows that 13,873,410 shares of this class were outstanding and that the seller’s position comes from a stock option acquired on January 13, 2026, involving 26,079 shares settled via a cashless transaction on January 14, 2026.